PLK1 and bladder transitional cell carcinoma: BI2536 is a Polo-like kinase 1 (PLK1) inhibitor with in vitro antitumor activity against BLCA cell lines RT4, 5637, and T24, preventing cell proliferation and clonogenicity, thereby significantly inhibiting BLCA growth and spread (Brassesco et al., 2013).